© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Venclexta alone or in combination with Rituxan improved progression-free survival in patients with chronic lymphocytic leukemia.
Long-term remission seen in children with leukemia and adults with lymphoma.
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease.
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
Customized cell therapy plus Imbruvica leads to high response rate.
ASH 2018 conference highlights precision medicine, machine learning and gut microbiome.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
